Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniasis

Drugs

Volumn 55, Issue 4, 1998, Pages 585-612

  Coukell, Allan J ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCUS; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; HYPOKALEMIA; IMMUNE DEFICIENCY; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; META ANALYSIS; MYCOSIS; NEPHROTOXICITY; NEUTROPHIL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CANDIDIASIS; DRUG CARRIERS; ECONOMICS, PHARMACEUTICAL; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, VISCERAL; LIPOSOMES; NEUTROPHILS;

EID: 0031955542     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855040-00008     Document Type: Article

References (115)

1. Richardson MD, Warnock DW. Fungal Infection: diagnosis and management. Oxford: Blackwell Scientific Publications. 1993
2. Viviani MA, Rizzardini G, Tortorano AM, et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 1994 Mar-Apr; 22: 137-42
3. de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994 May; 33: 907-16
4. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703
5. Proffitt RT, Adler-Moore J, Fujii G, et al. Stability and mode of action of Ambisome® (liposomal amphotericin B). J Control Release 1994 Jan; 28: 342-3
6. Pallister CJ, Johnson EM, Warnock DW, et al. In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes. J Antimicrob Chemother 1992 Sep; 30: 313-20
7. Schindler JJ, Warren RP, Allen SD, et al. Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice. Antimicrob Agents Chemother 1993 Dec; 37: 2716-21
8. Working Party of the British Society for Antimicrobial Chemotherapy. Working Party report: antifungal drug susceptibility testing. J Antimicrob Chemother 1995; 36: 899-909
9. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J Antimicrob Chemother 1996; 38: 561-78
10. Anaissie E, Paetznick V, Proffitt R, et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991 Aug; 10: 665-8
11. Karyotakis NC, Anaissie EJ. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother 1994 Nov; 38: 2660-2
12. Karyotakis NC, Anaissie EJ, Hachem R, et al. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis 1993 Nov; 168: 1311-3
13. van Etten EW, van den Heuvel-de-Groot C, Bakker-Woudenberg IA. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother 1993 Nov; 32: 723-39
14. Kretschmar M, Nichterlein T, Hof H. Ambisome is superior to amphotericin B in lipid suspensions for treatment of murine candidiasis [abstract]. 7th Eur Congr Clin Microbiol Infect Dis 1995: 155
15. Adler-Moore JP, Chiang S-M, Satorius A, et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother 1991 Oct; 28 Suppl. B: 63-71
16. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994 Feb; 169: 356-68
17. Leenders ACAP, de Marie S, ten Kate MT, et al. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 1996 Aug; 38: 215-25
18. Vassiloyanakopoulos A, Boutsikakis J, Mylonakis EE, et al. Comparative therapeutic efficacy of two amphotericin B liposomal forms in aspergillus fumigatus (AF) experimental endocarditis [abstract]. Clin Infect Dis 1995 Sep; 21: 779
19. Albert MM, Stahl-Carroll TL, Luther MF, et al. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 1995; 5 (1): 1-6
20. Clemons KV, Stevens DA. Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol 1993; 31 (5): 387-94
21. Clemons KV, Stevens DA. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother 1993 Sep; 32: 465-72
22. Albert MM, Adams K, Luther MJ, et al. Efficacy of AmBisome in murine coccidioidomycosis. J Med Vet Mycol 1994 Dec; 32: 467-71
23. Anaissie EJ, Hachem R, Karyotakis NC, et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother 1994 Nov; 38: 2541-4
24. Graybill JR, Bocanegra R. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother 1995 Aug; 39: 1885-7
25. Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 1996; 9 (1): 111-22
26. Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997; 41 (4): 752-6
27. Gangneux J-P, Sulahian A, Garin YJ-F. et al. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg 1996 Sep-Oct; 90: 574-7
28. Gradoni L, Davidson RN, Orsini S, et al. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target 1993; 1 (4): 311-6
29. Oliva G, Gradoni L, Ciaramella P, et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995 Dec; 36: 1013-9
30. Proffitt RT, Satorius A, Chiang S-M, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991 Oct; 28 Suppl. B: 49-61
31. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992 Oct; 23: 279-91
32. Heinemann V, Kähny B, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994; 14 Suppl. 5: S8-9
33. Walsh TJ, Bekersky I, Yeldandi V, et al. Pharmacokinetics of AmBisome in persistently febrile neutropenic patients receiving empirical antifungal therapy [abstract no. A13]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 1995 Sep 17-20; 3
34. NeXstar Pharmaceuticals Inc. AmBisome(R) (amphotericin B) lipossome for injection: prescribing information. Deerfield, IL, USA, Aug 1997
35. Ringdén O, Meunier F, Tolleman J, et al. Efficacy of amphotericin B encapsulated in liposomes (Ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991 Oct; 28 Suppl. B: 73-82
36. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin-B (Ambisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transpl 1990 Jun; 4: 167-75
37. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome®) in rabbits [abstract]. Antimicrob Agents Chemother 1994 Apr; 38: 713-8
38. Gonzalez C, Sein T, Bacher J, et al. Penetration of lipid formulations of amphotericin B into cerbrospinal fluid and brain tissue [abstract no. A-90]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 1997 Sep 28-Oct 1; Toronto, 19
39. Tomlin M, Priestley GS. Elimination of liposomal amphotericin by hemodiafiltration [letter]. Intensive Care Med 1995 Aug; 21: 699-700
40. Humphreys H, Oliver DA, Winter R, et al. Lipososmal amphotericin B and continuous venous-venous haemofiltration [letter]. J Antimicrob Chemother 1994 May; 33: 1070-1
41. Meunier F. Targeting fungi: a challenge. Am J Med 1995 Dec 29; 99 Suppl. 6A: 60S-7S
42. Tollemar J, Ringdén O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993 Dec; 12: 577-82
43. Tollemar J, Höckerstedt K, Ericzon B-G, et al. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long term results of a randomized, placebo-controlled trial. Transplant Proc 1995 Feb; 27: 1195-8
44. Walsh T, Bodensteiner D, Hiemenz J, et al. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients [abstract no. LM-90]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 1997 Sep 28-Oct 1; Toronto, 381
45. Prentice HG, Hahn IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8
46. Berenguer J, Muñoz, P, Parras F, et al. Treatment of deep mycoses with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 1994 Jun; 13: 504-7
47. Böhme A, Hoelzer D. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Mycoses 1996; 39: 419-26
48. Heinemann V, Pyka S, Bosse D, et al. Liposomal amphotericin B (AmBisome): clinical safety and efficacy [abstract]. Onkologie 1995 Oct; 18 Suppl. 2: 198
49. Krüger W, Stockschläder M, Rüssmann B, et al. Experience with liposomal amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 1995 Nov; 91: 684-90
50. Mills W, Chopra R, Linch DC, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994 Apr; 86: 754-60
51. Nowoczyn V, Ritter J, Boos J, et al. Liposomal amphotericin B (ambisome) in neutropenic children with hematological malignancies and systemic fungal infections [abstract]. Med Pediatr Oncol 1992; 20 (5): 376
52. Ringdén O, Tollemar J, Dahllöf G, et al. High cure rate of invasive fungal infections in immunocompromised children using ambisome. Transplant Proc 1994 Feb; 26: 175-7
53. Leenders ACAP, Daenen S, Jansen RLH, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B in the treatment of neutropenia-associated invasive fungal infections [abstract]. Trends in Invasive Fungal Infections 4: 1997 Nov 5; Barcelona
54. Tollemar J, Ringdén O, AmBisome(Rm) Users Group. Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (Ambisome(Rm)). Drug Invest 1992; 4 (3): 232-8
55. Ellis M, Spence D, Meunier F, et al. Randomised multicentre trial of 1 mg/kg (LD) versus 4 mg/kg(HD) liposomal amphotericin B (AmBisome) (LAB) in the treatment of invasive aspergillosis (IA): EORTC protocol 19923 [abstract no. LM39]. 36th Interscienee Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology: 1996 Sep 15-19; New Orleans
56. Devecioglu Ö, Özgen Ü, Agaoglu L, et al. Clinical experience with amphotericin B (conventional & liposomal) in febrile neutropenic children [abstract]. Can J Infect Dis 1995 Ju; 6 Suppl. C: 365C
57. Dornbusch HJ, Urban CE, Pinter H, et al. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr Hematol Oncol 1995 Nov-Dec; 12: 577-86
58. Pasic S, Flannagan L, Cant AJ. Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Bone Marrow Transplant 1997; 19: 1229-32
59. Evdoridou J, Roilides E, Bibashi E, et al. Multifocal osteoarthritis due to Candida tilhituns in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997; 25 (2): 44-8
60. Lazar JT, Ksionski GE. Efficacy of safety of AmBisome (liposomal amphotericin B) in primary episodes of cryptococcosis in patients with HIV infection [abstract no. W.B.2177). 7th International Conference on AIDS: 1991 Jun 16-21; N
61. Mota-Miranda A, Gomes H, Marques R, et al. Liposomal amphotericin B in the treatment of opportunistic fungal infections. Rev Esp Quimioter 1994 Jun; 7: 146-9
62. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993 Jun; 7: 829-35
63. Codeluppi M, Mussini C, Borghi V, et al. Liposomal amphotericin B in therapy in patients with AIDS [abstract no. P34]. Glasgow AIDS Meeting 1992 Nov
64. Leenders ACAP, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meniingitis. AIDS 1997; 11: 1463-71
65. Leggiadro RJ, Kline MW, Hughes WT. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991; 10: 658-62
66. Manfredi R, Coronado OV, Mastroianni A, et al. Liposomal amphotericin B and recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Int J STD AIDS 1997; 8: 406-8
67. Fisher NC, Mutimer DJ. Targeted and empirical liposomal amphotericin B therapy in liver transplantation: a 2-year review [abstract no. 1537]. Hepatology 1996; 24 (4, Pt. 2) Program Suppl.: 511A
68. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995 May 22; 155: 1093-8
69. Munckhof W, Jones R, Tosolini FA, et al. Cure of Rhizopus sinusitis in a liver transplant recipient w ith liposomal amphotericin B [letter]. Clin Infect Dis 1993 Jan; 16: 183
70. Cofrancesco E, Boschetti C, Viviani MA, et al. Efficacy of liposomal amphotericin-B (AmBisome) in the eradication of Fusarium infection in a leukaemic patient. Haematologica 1992 May-Jun; 77: 280-3
71. Ellis ME, Clink H, Younge D, et al. Successful combined surgical and medical treatment of fusarium infection after bone marrow transplantation. Scand J Infect Dis 1994; 26: 225-8
72. Harten P, Baron Y, Euler HH. Liposomal amphotericin B therapy in disseminated histoplasmosis [letter]. Arch Intern Med 1995 Jul 24; 155: 1556
73. Berlanga JJ, Querol S, Gallardo D, et al. Successful treatment of Curvularia sp infection in a patient with primarily resistant acute promyelocytic leukemia. Bone Marrow Transplant 1995 Oct; 16: 617-9
74. Davidson RN, di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994 Feb; 87: 75-81
75. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996 Jun; 22: 938-43
76. di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131: 271-7
77. Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996 Mar; 32: 133-7
78. Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995 Jul; 21: 188-93
79. Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome Rm) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996 May-Jun; 90: 319-22
80. Ringdén O, Andström E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994; 14 Suppl. 5: S10-14
81. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: prevention and management. Drug Sat 1992 Sep-Oct; 7: 323-63
82. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991 Oct; 28 Suppl. B: 83-91
83. Bates CM, Carey PB, Hind CRK. Anaphylaxis due to liposomal amphotericin (AmBisome) [letter]. Genitourin Med 1995 Dec; 71; 414
84. Laing RBS, Milne LJR, Leen LJR, et al. Anaphylactic reactions to liposomal amphotericin [letter]. Lancet 1994 Sep 3; 344: 682
85. Arning M, Heer-Sonderhoff AH, Wehmeier A. et al. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995 Jan; 14: 41-3
86. Ringdén O, Andström E, Remberger M, et al. Allergic reactions and other rare side-effects of liposomal amphotericin [letter]. Lancet 1994 Oct 22; 344: 1156-7
87. Torre I, López-Herce J, Vázquez P. Anaphylactic reaction to liposomal amphotericin B in children. Ann Pharmacother 1996 Sep; 30: 1036-7
88. Aguado JM, Hidalgo M, Moya I, et al. Ventricular arrhythmias with conventional and liposomal amphotericin [letter]. Lancet 1993 Nov 13; 342: 1239
89. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995 Apr; 20: 755-61
90. Hoeprich PD, Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 1992 Mar; 14 Suppl. 1: S114-9
91. NeXstar Pharmaceuticals Limited. AmBisome: summary of product characteristics. Cambridge, England. 1996 Feb 07
92. NeXstar Pharmaceuticals Inc. Ambisome(R) (liposomal amphotericin B.P.): product monograph. Boulder, Colorado, USA, 1995
93. Percira da Silva L, Videira Amaral JM, Cordeiro Ferreira N. Which is the most appropriate dosage of liposomal Amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low hirth weight? [letter; comment]. Pediatrics 1993 Jun; 91: 1217-8
94. Lackner H, Schwinger W, Urban C, et al. Liposoinal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics 1942 Jun; 89(Pt 2): 1259-61
95. Leibovitz E, Juster A, Amitay A, et al. Liposomal amphotericin B (AmBisome) in the treatment of disseminated fungal infections in very low birth weight (VLBW) infants [abstract no. 4112]. 20th International Congress of Chemotherapy: 1997 Jun 29-JuI 3; Sydney, 128
96. Drugs used in the treatment of infection. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain. 1997 Sep; 230-292
97. Tollemar J, Ringdén O. Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Sat 1995 Oct; 13: 207-18
98. Persson U, Tennvall GR, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992 Dec; 2: 500-8
99. Boogaerts M, Tormans G, Maes E, et al. Cost-effectiveness analysis of Ambisome (AMB) vs amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children [abstract no. 55-IV]. Blood 1996 Nov 15; 88 Suppl. 1: 501a
100. Stewart A, Powles R, Hewetson M, et al. Costs of antifungal prophylaxis after bone marrow transplantation: a model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections. Pharmacoeconomics 1995 Oct; 8: 350-61
101. Richardson MD. Systemic fungal infections [68572]. Care Critically III 1994; 10: 258-61
102. Denning DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991; 28 Suppl. B: 1-16
103. Herbrecht R. The changing epidemiology of fungal infections: are the lipid-based forms of amphotericin B an advance? Eur J Haematol 1996; 56 Suppl. 57: 12-7
104. Uzun O, Anaissie EJ. Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis 1996; 22 Suppl. 2: S95-S101
105. Swerdloff JN, Filler SG, Edwards Jr. JE. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993; 17 Suppl. 2: S456-67
106. Beyer J, Schwartz S, Heinemann V, et al. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother 1994 May; 38: 911-7
107. Mahgoub ES. Agents of mycetoma. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. 4th ed. ed. Vol. 2. New York: Churchill Livingstone, 1995: 2327-40
108. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22 Suppl. 2: S119-23
109. Abu-Salah KM. Amphotericin B: an update. Br J Biomed Sci 1996 Jun; 53: 122-33
110. British Society for Antimicrobial Chemotherapy Working Party. Antifungal chemotherapy in patients with acquired immunodeficiency syndrome. Lancet 1942; 340: 648-51
111. Gallis HA. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin Infect Dis 1996 May; 22 Suppl. 2: S145-7
112. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997; 314: 1238-44
113. Pearson RD, de Queiroz Sousa A. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. 4th ed. ed. Vol. 2. New York: Churchill Livingstone, 1995: 2428-42
114. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995; 73 (2): 191-7
115. Ashford RW, Desjeux P, deRaadt P. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol Today 1992; 8 (3): 104-5